How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,961 results for

Ketoconazole

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. (Abstract)

Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. Bosutinib (SKI-606), a dual inhibitor of Src and Abl tyrosine kinases, is being developed for the treatment of chronic myelogenous leukemia. The effect of coadministration of ketoconazole on the pharmacokinetic (PK) profile of bosutinib was evaluated in an open-label, randomized, 2-period, crossover study. Healthy subjects (fasting) received a single dose of oral bosutinib 100 mg alone and with multiple once (...) -daily doses of oral ketoconazole 400 mg. PK sampling occurred through 96 hours. The least square geometric mean treatment ratios (90% confidence interval [CI]) of C(max(bosutinib+ketoconazole))/C(max(bosutinib alone)), AUC(T(bosutinib+ketoconazole))/AUC(T(bosutinib alone)), and AUC((bosutinib+ketoconazole))/AUC((bosutinib alone)) were assessed. Compared with bosutinib administered alone, coadministration with ketoconazole increased bosutinib C(max) 5.2-fold, AUC(T) 7.6-fold, and AUC 8.6-fold

2011 Journal of clinical pharmacology Controlled trial quality: uncertain

162. Identification of Ketoconazole as an AhR-Nrf2 Activator in Cultured Human Keratinocytes: The Basis of Its Anti-Inflammatory Effect. Full Text available with Trip Pro

Identification of Ketoconazole as an AhR-Nrf2 Activator in Cultured Human Keratinocytes: The Basis of Its Anti-Inflammatory Effect. Ketoconazole (KCZ) has been shown to exhibit anti-inflammatory effects in addition to its inhibitory effects against fungi; however, the underlying molecular mechanism remains poorly understood. Aryl hydrocarbon receptor (AhR), a receptor that is activated by polycyclic aromatic hydrocarbons (PAHs) and halogenated aromatic hydrocarbons such as dioxin, is a sensor

2011 Journal of Investigative Dermatology

163. Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex

Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01323465 Recruitment Status : Completed First Posted : March 25, 2011 Last Update

2011 Clinical Trials

164. Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01324310 Recruitment Status : Completed First Posted : March 29, 2011 Results First Posted : May 15, 2013 Last Update

2011 Clinical Trials

165. Effect of Ketoconazole on Breathlessness

Effect of Ketoconazole on Breathlessness Effect of Ketoconazole on Breathlessness - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect of Ketoconazole on Breathlessness (KetoRLB) The safety and scientific (...) Study Description Go to Brief Summary: Beta-endorphins, which are naturally occurring narcotic substances, have been shown to alter the perception of breathlessness. Oral ketoconazole, an antifungal antibiotic, increases blood levels of beta-endorphins. The study hypothesis is that oral ketoconazole will reduce ratings of breathlessness induced by resistive breathing loads. Condition or disease Intervention/treatment Phase Chronic Obstructive Pulmonary Disease Drug: ketoconazole Drug: inert powder

2011 Clinical Trials

166. To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)

To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban) To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01405989 Recruitment Status : Completed First Posted : July 29, 2011 Last Update Posted : March 5, 2014 Sponsor

2011 Clinical Trials

167. A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects

A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01363778 Recruitment Status : Completed First Posted : June 2, 2011 Last

2011 Clinical Trials

168. Drug-drug Interaction Study (CKD-501, Ketoconazole)

Drug-drug Interaction Study (CKD-501, Ketoconazole) Drug-drug Interaction Study (CKD-501, Ketoconazole) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Drug-drug Interaction Study (CKD-501, Ketoconazole (...) Description Go to Brief Summary: The purpose of this study is to assess the effect of Ketoconazole on the pharmacokinetic characteristics of CKD-501 in healthy subject. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: CKD-501, Ketoconazole Phase 1 Detailed Description: From day 1 to day 5, Ketoconazole 200mg is administered twice daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg is co-administered Group 1 patients at period 1. After 28 day-break, period

2011 Clinical Trials

169. Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A. (Abstract)

Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A. Based on in vitro data with isolated cytochrome P450 (CYP) isoenzymes, alitretinoin interacts only with CYP3A4, and the potential for drug-drug interactions is considered negligible.To confirm in humans the lack of potential interactions between CYP3A4 and alitretinoin in vivo.This was a multiple-dose, open-label, parallel-group, single-centre study, which enrolled 54 healthy male volunteers aged (...) 18-45 years. Subjects were divided into three groups, with 18 in each group: group 1 received either alitretinoin 30 mg and ketoconazole 200 mg, group 2 alitretinoin 30 mg and simvastatin 40 mg, and group 3 alitretinoin 30 mg and ciclosporin A 300-mg.At the highest therapeutic dose of 30 mg, alitretinoin had no significant effect on the pharmacokinetics (PK) of ketoconazole and ciclosporin A. There was a significant but not clinically relevant effect of simvastatin on the area under the curve

2011 Clinical and experimental dermatology Controlled trial quality: uncertain

170. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Full Text available with Trip Pro

Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Tamsulosin metabolism involves both CYP2D6 and 3A4. However, data on potential drug-drug interactions between tamsulosin and inhibitors of CYP2D6 and 3A4 are limited and information on potential pharmacodynamic consequences of such pharmacokinetic interactions is missing.This study provides information on the drug-drug interactions of tamsulosin with strong (...) CYP2D6 and strong CYP3A4 inhibitors after single dose administration in healthy subjects.To determine the effect of the strong CYP2D6 inhibitor paroxetine and strong CYP3A4 inhibitor ketoconazole on the pharmacokinetics and safety (orthostatic challenge) of tamsulosin.Two open-label, randomized, two-way crossover studies were conducted in healthy male volunteers (extensive CYP2D6 metabolizers).Co-administration of multiple oral doses of 20 mg paroxetine once daily with a single oral dose of the 0.4

2011 British journal of clinical pharmacology Controlled trial quality: uncertain

171. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. Full Text available with Trip Pro

Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. The primary objective was to evaluate the pharmacokinetics of a single dose of neratinib, a potent, low-molecular-weight, orally administered, irreversible pan-ErbB (ErbB-1, -2, -4) receptor tyrosine kinase inhibitor, during co-administration with ketoconazole, a potent CYP3A4 inhibitor.This was an open-label, randomized, two-period, crossover study. Fasting healthy adults received a single oral (...) dose of neratinib 240 mg alone and with multiple oral doses of ketoconazole 400 mg. Blood samples were collected up to 72 h after each neratinib dose. Plasma concentration data were analyzed using a noncompartmental method. The least square geometric mean ratios [90% confidence interval (CI)] of C(max) (neratinib+ketoconazole): C(max) (neratinib alone), and AUC(neratinib+ketoconazole): AUC(neratinib alone) were assessed.Twenty-four subjects were enrolled. Compared with neratinib administered alone

2011 British journal of clinical pharmacology Controlled trial quality: uncertain

172. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study. (Abstract)

Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Topical antifungals and corticosteroids are the mainstay of treatment for seborrhoeic dermatitis. The short-contact clobetasol propionate 0·05% shampoo (CP) is an efficacious and safe once-daily treatment for scalp psoriasis.To evaluate the efficacy and safety of CP alone and combined (...) with ketoconazole shampoo 2% (KC) in the treatment of moderate to severe scalp seborrhoeic dermatitis.This randomized and investigator-blinded study consisted of three phases, each lasting 4 weeks. During the treatment phase, subjects were randomized to receive KC twice weekly (K2), CP twice weekly (C2), CP twice weekly alternating with KC twice weekly (C2 + K2) or CP four times weekly alternating with KC twice weekly (C4+K2). All subjects received KC once weekly during the maintenance phase and were untreated

2011 The British journal of dermatology Controlled trial quality: uncertain

173. Synergistic effects of tetrandrine on the antifungal activity of topical ketoconazole cream in the treatment of dermatophytoses: a clinical trial. (Abstract)

Synergistic effects of tetrandrine on the antifungal activity of topical ketoconazole cream in the treatment of dermatophytoses: a clinical trial. To evaluate the synergistic effects of tetrandrine (TET) on the antifungal activity of topical ketoconazole (KCZ) in the treatment of dermatophytoses.The minimum inhibitory concentrations (MICs) for KCZ and combined KCZ and TET were compared in vitro. A randomized, double-blind trial was conducted among 97 patients with dermatophytoses who were

2011 Chinese journal of integrative medicine Controlled trial quality: uncertain

174. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv. (Abstract)

Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv. Visceral leishmaniasis (VL) caused by the parasite Leishmania donovani, is a potentially fatal disease. It is characterized by prolonged fever, enlarged spleen and liver, substantial weight loss and progressive anemia. Available drugs are toxic, costly and require prolonged treatment duration viz; 28 days of oral treatment with miltefosine, 30 days (...) infusion with Amphotericin B and 21 days intramascular with paromomycin sulfate. Drug combination for VL clinically proved to shorten the duration of treatment. The efficacy of drugs is also compromised due to suppression of immune function during the course of infection. To combat this situation leishmanicidal efficacy of already marketed standard antifungal drug, ketoconazole under the approach of 'therapeutic switching' in combination with standard antileishmanial drug, miltefosine and a potent

2011 Acta Tropica

175. What is evidence for the effective use of ketoconazole shampoo in cradle cap?

What is evidence for the effective use of ketoconazole shampoo in cradle cap? What is evidence for the effective use of ketoconazole shampoo in cradle cap? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search (...) images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com What is evidence for the effective use of ketoconazole shampoo in cradle cap? The CKS guideline on seborrhoeic dermatitis (1) states on the management of seborrhoeic dermatitis in infants: “CKS could find no trial evidence for ketoconazole

2010 TRIP Answers

176. Ketoconazole

Ketoconazole Ketoconazole - Wikipedia Ketoconazole From Wikipedia, the free encyclopedia Ketoconazole (2 R ,4 S )-(+)-ketoconazole (top) (2 S ,4 R )-(−)-ketoconazole (bottom) Clinical data Pronunciation Nizoral, others Synonyms R-41400; KW-1414 / : : (Risk not ruled out) ( ), ( , , ) ( ) ( ) ( ) Legal status data : 37–97% 84 to 99% Extensive (predominantly oxidation, O -dealkylation) N -deacetyl ketoconazole Biphasic (major) and Identifiers 1-[4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1 (...) -ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone Y Y Y Y Y Y KTN ( , ) Chemical and physical data C 26 H 28 Cl 2 N 4 O 4 531.431 g/mol g·mol −1 3D model ( ) O=C(N5CCN(c4ccc(OC[C@@H]1O[C@](OC1)(c2ccc(Cl)cc2Cl)Cn3ccnc3)cc4)CC5)C InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1 Y Key:XMAYWYJOQHXEEK-OZXSUGGESA-N Y N Y Ketoconazole is an medication used

2012 Wikipedia

177. Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

, ketoconazole) ? radiopharmaceutical substances (e. g. strontium-89) or immunotherapy (e.g. sipuleucel-T) for nmCRPC ? chemotherapy (except adjuvant/neoadjuvant) ? second-generation anti-androgens (e.g. enzalutamide) Concomitant treatment not recommended: ? strong CYP3A4 inducers and CYP3A4 substrates with narrow therapeutic indices ? strong CYP2C8 inhibitors (e. g. gemfibrozil) not allowed: ? approved drugs for prevention of skeletal-related events in solid tumours (e.g. denosumab); allowed for treatment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

178. Precocious puberty

: gonadotrophin-dependent (GDPP; due to premature activation of the hypothalamo-pituitary-gonadal axis) and gonadotrophin-independent (GIPP; due to autonomous secretion of sex steroids). History should be directed dependent on whether puberty is consonant or disconsonant (i.e., whether the pattern of endocrine change is the same as in normal puberty or not). Treatment of GDPP is usually straightforward with gonadotrophin-releasing hormone agonists. GIPP is more difficult to treat; may require ketoconazole

2019 BMJ Best Practice

179. Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V

medication considered necessary for the patient’s wellbeing and not interacting with the study medication could be administered at the physician’s discretion (e.g. antiemetics) ? bisphosphonates or denosumab were allowed as long as their intake started at least 5 days prior to randomization Non-permitted concomitant treatment ? further cancer treatments (including investigational drugs) ? CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>